Moomoo AI 已提取核心信息
Heart Test Laboratories, Inc. (HSCS), a Texas-based medical technology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the potential sale of up to 34,684,859 shares of its common stock. The shares include those previously issued to certain selling stockholders and those that may be issued to Lincoln Park Capital Fund, LLC pursuant to a purchase agreement. The company will not receive proceeds from the selling stockholders' shares, except for any proceeds from the exercise of warrants. However, proceeds from the sale of shares to Lincoln Park will be used for working capital and general corporate purposes. The shares are being offered through a prospectus, and the offering will be made only by means of the prospectus. The registration statement includes details about the company's financials, risks, and the terms of the offering. The shares of common stock are listed on the Nasdaq Capital Market under the symbol 'HSCS'.
Heart Test Laboratories, Inc. (HSCS), a Texas-based medical technology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the potential sale of up to 34,684,859 shares of its common stock. The shares include those previously issued to certain selling stockholders and those that may be issued to Lincoln Park Capital Fund, LLC pursuant to a purchase agreement. The company will not receive proceeds from the selling stockholders' shares, except for any proceeds from the exercise of warrants. However, proceeds from the sale of shares to Lincoln Park will be used for working capital and general corporate purposes. The shares are being offered through a prospectus, and the offering will be made only by means of the prospectus. The registration statement includes details about the company's financials, risks, and the terms of the offering. The shares of common stock are listed on the Nasdaq Capital Market under the symbol 'HSCS'.
总部位于德克萨斯州的医疗技术公司Heart Test Laboratories, Inc.（HSCS）已向美国证券交易委员会（SEC）提交了注册声明，可能出售多达34,684,859股普通股。这些股票包括先前向某些出售股东发行的股票，以及根据收购协议可能向林肯公园资本基金有限责任公司发行的股票。除行使认股权证的任何收益外，公司不会从出售股东的股票中获得收益。但是，向林肯公园出售股票的收益将用于营运资金和一般公司用途。这些股票是通过招股说明书发行的，并且只能通过招股说明书进行发行。注册声明包括有关公司财务状况、风险和发行条款的详细信息。普通股在纳斯达克资本市场上市，股票代码为 “HSCS”。
总部位于德克萨斯州的医疗技术公司Heart Test Laboratories, Inc.（HSCS）已向美国证券交易委员会（SEC）提交了注册声明，可能出售多达34,684,859股普通股。这些股票包括先前向某些出售股东发行的股票，以及根据收购协议可能向林肯公园资本基金有限责任公司发行的股票。除行使认股权证的任何收益外，公司不会从出售股东的股票中获得收益。但是，向林肯公园出售股票的收益将用于营运资金和一般公司用途。这些股票是通过招股说明书发行的，并且只能通过招股说明书进行发行。注册声明包括有关公司财务状况、风险和发行条款的详细信息。普通股在纳斯达克资本市场上市，股票代码为 “HSCS”。
有用
没用